Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Brain and BrainPET 2015
Daytime sleepiness versus fatigue in patients with multiple sclerosis: A systematic review on the Epworth sleepiness scale as an assessment tool.
Extended interval dosing of natalizumab in multiple sclerosis.
Tumefactive multiple sclerosis presenting with tonic-clonic seizure.
Effects of Interferon β-1a and Interferon β-1b Monotherapies on Selected Serum Cytokines and Nitrite Levels in Patients with Relapsing-Remitting Multiple Sclerosis: A 3-Year Longitudinal Study.
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study.
Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression.
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.
Epigenetics of Multiple Sclerosis: An Updated Review.
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis.
Acorda Therapeutics announces Hatch-Waxman extension of AMPYRA® (dalfampridine) sustained-release formulation patent
Episode 24 with Professor Aksel Siva discussing asymptomatic MS
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.
Biogen Idec receives notification of PDUFA date extension
Artesunate Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibiting Leukocyte Migration to the Central Nervous System.
Optical Coherence Tomography in Multiple Sclerosis.
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
12th International Conference on Myasthenia Gravis and Related Disorders
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK.
Fatigue and Comorbidities in Multiple Sclerosis.
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.

Pages